Arigos Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
About Arigos Pharmaceutical
Arigos Pharmaceutical Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 December 2021 (Three years and one month 12 days old ). Its registered office is in Kamrup, Assam, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sahid Laskar, Sahadot Laskar, Nazia Kausor, and Two other members serve as directors at the Company.
Company Details
-
Location
Kamrup, Assam, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909AS2021PTC022348
-
Company No.
022348
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Dec 2021
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Shillong
Industry
Who are the key members and board of directors at Arigos Pharmaceutical?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sahid Laskar
|
Director | 20-Dec-2021 | Current |
|
Sahadot Laskar
|
Director | 20-Dec-2021 | Current |
|
Nazia Kausor
|
Director | 09-Sep-2022 | Current |
|
Maksud Barbhuiya
|
Director | 17-Nov-2023 | Current |
| Polok Das | Director | 05-Nov-2024 | Current |
Financial Performance of Arigos Pharmaceutical.
Enhance accessibility to Arigos Pharmaceutical's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arigos Pharmaceutical?
Unlock access to Arigos Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Fms Skilful Healthcare Private LimitedNazia Kausor is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Arigos Pharmaceutical?
Arigos Pharmaceutical has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arigos Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arigos Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
